VISTAGEN THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Earnings Per Share, Basic and Diluted of -$0.05 per share for the 3-month period ending 2021-12-31, per its 10-Q filed 2022-02-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-02-10
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.05.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.07.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.04.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.20.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$0.49.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$0.50.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$0.90.
- VISTAGEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$1.12.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$0.05 10-Q · filed 2022-02-10 | -$0.12 derived: net income ÷ weighted average shares · filed 2023-06-28 | -$0.16 10-Q · filed 2022-02-10 | -$0.34 derived: net income ÷ weighted average shares · filed 2023-06-28 |
| 2021-09-30 | -$0.07 10-Q · filed 2021-11-10 | -$0.11 10-Q · filed 2021-11-10 | -$0.29 derived: net income ÷ weighted average shares · filed 2023-06-28 | -$0.37 derived: net income ÷ weighted average shares · filed 2023-06-28 |
| 2021-06-30 | -$0.04 10-Q · filed 2021-08-12 | -$0.22 derived: net income ÷ weighted average shares · filed 2023-06-28 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-06-28 | -$0.39 derived: net income ÷ weighted average shares · filed 2023-06-28 |
| 2021-03-31 | -$0.20 10-K · filed 2021-06-29 | -$0.31 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$0.40 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$0.49 10-K · filed 2021-06-29 |
| 2020-12-31 | -$0.07 10-Q · filed 2022-02-10 | -$0.13 derived: net income ÷ weighted average shares · filed 2022-02-10 | -$0.19 10-Q · filed 2022-02-10 | -$0.27 derived: net income ÷ weighted average shares · filed 2022-02-10 |
| 2020-09-30 | -$0.05 10-Q · filed 2021-11-10 | -$0.12 10-Q · filed 2021-11-10 | -$0.19 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$0.33 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2020-06-30 | -$0.07 10-Q · filed 2021-08-12 | -$0.14 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$0.28 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$0.41 derived: net income ÷ weighted average shares · filed 2021-08-12 |
| 2020-03-31 | -$0.08 10-K · filed 2021-06-29 | -$0.22 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.35 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.50 10-K · filed 2021-06-29 |
| 2019-12-31 | -$0.15 10-K · filed 2021-06-29 | -$0.28 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.43 10-Q · filed 2021-02-11 | -$0.60 derived: net income ÷ weighted average shares · filed 2021-06-29 |
| 2019-09-30 | -$0.13 10-K · filed 2021-06-29 | -$0.29 10-Q · filed 2020-11-12 | -$0.45 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.68 derived: net income ÷ weighted average shares · filed 2021-06-29 |
| 2019-06-30 | -$0.15 10-K · filed 2021-06-29 | -$0.32 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.55 derived: net income ÷ weighted average shares · filed 2021-06-29 | -$0.83 derived: net income ÷ weighted average shares · filed 2021-06-29 |
| 2019-03-31 | -$0.17 10-K · filed 2020-06-29 | -$0.41 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$0.70 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$0.90 10-K · filed 2020-06-29 |
| 2018-12-31 | -$0.24 10-K · filed 2020-06-29 | -$0.54 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$0.75 10-Q · filed 2020-02-13 | -$0.94 derived: net income ÷ weighted average shares · filed 2020-06-29 |
| 2018-09-30 | -$0.30 10-K · filed 2020-06-29 | -$0.50 10-Q · filed 2019-11-07 | -$0.69 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$0.94 derived: net income ÷ weighted average shares · filed 2020-06-29 |
| 2018-06-30 | -$0.20 10-K · filed 2020-06-29 | -$0.39 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$0.62 derived: net income ÷ weighted average shares · filed 2020-06-29 | -$1.01 derived: net income ÷ weighted average shares · filed 2020-06-29 |
| 2018-03-31 | -$0.19 10-K · filed 2019-06-25 | -$0.42 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$0.84 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$1.12 10-K · filed 2019-06-25 |
| 2017-12-31 | -$0.25 10-K · filed 2019-06-25 | -$0.73 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$1.03 10-Q · filed 2019-02-12 | -$1.35 derived: net income ÷ weighted average shares · filed 2019-06-25 |
| 2017-09-30 | -$0.53 10-K · filed 2019-06-25 | -$0.82 10-Q · filed 2018-10-29 | -$1.15 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$1.50 derived: net income ÷ weighted average shares · filed 2019-06-25 |
| 2017-06-30 | -$0.28 10-K · filed 2019-06-25 | -$0.60 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$0.94 derived: net income ÷ weighted average shares · filed 2019-06-25 | -$1.35 derived: net income ÷ weighted average shares · filed 2019-06-25 |
| 2017-03-31 | -$0.32 10-K · filed 2018-06-26 | -$0.67 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$1.08 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$1.54 10-K · filed 2018-06-26 |
| 2016-12-31 | -$0.34 10-K · filed 2018-06-26 | -$0.76 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$1.23 10-Q · filed 2018-02-12 | -$3.09 derived: net income ÷ weighted average shares · filed 2018-06-26 |
| 2016-09-30 | -$0.42 10-K · filed 2018-06-26 | -$0.91 10-Q · filed 2017-11-09 | -$3.02 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$4.42 derived: net income ÷ weighted average shares · filed 2018-06-26 |
| 2016-06-30 | -$0.51 10-K · filed 2018-06-26 | -$3.34 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$5.17 derived: net income ÷ weighted average shares · filed 2018-06-26 | -$9.06 derived: net income ÷ weighted average shares · filed 2018-06-26 |
| 2016-03-31 | -$4.44 10-K · filed 2017-06-29 | -$6.62 derived: net income ÷ weighted average shares · filed 2017-06-29 | -$11.66 derived: net income ÷ weighted average shares · filed 2017-06-29 | -$29.08 10-K · filed 2017-06-29 |
| 2015-12-31 | -$1.95 10-K · filed 2017-06-29 | -$7.08 derived: net income ÷ weighted average shares · filed 2017-06-29 | -$25.45 10-Q · filed 2017-02-13 | |
| 2015-09-30 | -$5.26 10-K · filed 2017-06-29 | -$24.21 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$19.23 10-K · filed 2017-06-29 | |||
| 2014-06-30 | -$3.70 10-Q · filed 2015-08-14 | |||
| 2013-09-30 | -$0.07 10-Q · filed 2013-11-14 | -$0.06 10-Q · filed 2013-11-14 | ||
| 2012-09-30 | -$0.12 10-Q · filed 2013-11-14 | -$0.22 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |